PARKINSON’S DISEASE
Abstract
Parkinson's disease is a degenerative disorder of the central nervous system that often impairs the
sufferer's motor skills, speech, and other functions. Parkinson's disease affects movement (motor
symptoms). Other typical symptoms include disorders of mood, behaviour, thinking, and sensation (nonmotor
symptoms). The symptoms of Parkinson's disease result from the greatly reduced activity of the
dopaminergic neurons, which are primarily in the pars compacta region of the substantia nigra. Reviews
of depression estimate its occurrence in anywhere from 20-80% of cases. PD is not considered to be a
fatal disease by itself, but it progresses with time.
Full Text:
PDFReferences
Jankovic J (April 2008). "Parkinson's disease: clinical features and diagnosis". J. Neurol. Neurosurg. Psychiatr. 79 (4): 368–76.
National Institute for Health and Clinical Excellence. Clinical guideline 35: Parkinson's disease. London, June 2006.
Lepoutre A, Devos D, Blanchard-Dauphin A, et al (2006). "A specific clinical pattern of camptocormia in Parkinson's disease". J. Neurol. Neurosurg. Psychiatr. 77 (11): 1229–34.
Fox, Michael (2003). Lucky Man: A Memoir. Hyperion. pp. 214.
Deuschl G, Goddemeier C (1998). "Spontaneous and reflex activity of facial muscles in dystonia, Parkinson's disease, and in normal subjects". J. Neurol. Neurosurg. Psychiatr. 64 (3): 320–4.
Lieberman A (2006). "Depression in Parkinson's disease -- a review". Acta Neurol Scand 113 (1): 1–8.
Ishihara L, Brayne C (2006). "A systematic review of depression and mental illness preceding Parkinson's disease". Acta Neurol Scand 113 (4): 211–20.
Pell M (1996). "On the receptive prosodic loss in Parkinson's disease". Cortex 32 (4): 693–704.
Frank MJ (2005). "Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism". Journal of cognitive
neuroscience 17 (1): 51–72.
Gupta A, Bluhm R (2004). "Seborrheic dermatitis". Journal of the European Academy of Dermatology and Venereology : JEADV 18 (1): 13–26.
Parkinson’s disease.eMedicine Health.Sept 15,2009.
Parkinson's Disease Mechanism Discovered," HHMI Research News June 22, 2006.
Jenner P (1998). "Oxidative mechanisms in nigral cell death in
Parkinson's disease". Mov. Disord. 13 Suppl 1: 24–34.
Masliah E, Rockenstein E, Veinbergs I, et al (2000). "Dopaminergic loss and inclusion body formation in alphasynuclein
mice: implications for neurodegenerative disorders". Science 287
(5456): 1265–9.
CS Chan "Rejuvenation protects neurons in mouse models of Parkinson's disease" Nature.Volume 447:10811- 89,2007.
R. Cilia et al. (2006). "Long-term Efficacy of Entacapone in Patients with Parkinson's Disease and Motor Fluctuations
- A Six-Year Clinical Follow-Up Study". http://www.touchneurology.com/articles.cf m?article_id=5728&level=2.
Marras C, McDermott M, Rochon P, Tanner C, Naglie G, Rudolph A, Lang A (2005). "Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort". Neurology 64 (1): 87–93.
Goetz CG, Stebbins GT (1995). "Mortality and hallucinations in nursing home patients with advanced Parkinson's disease". Neurology 45 (4): 669–71.
DOI: http://dx.doi.org/10.30742/jikw.v0i1.2151
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Titiek Sunaryati
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Jurnal Ilmiah Kedokteran Wijaya Kusuma is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
